Please login to the form below

Not currently logged in
Email:
Password:

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

More good news, and some bad, for Merck’s Keytruda

More good news, and some bad, for Merck’s Keytruda

It’s the second priority review filing for Keytruda to get underway at the FDA in a week, coming after the PD-1 inhibitor was filed as a first-line treatment ... The rare setback for Keytruda comes as it has started to show signs of lengthening its new

Latest news

  • Merck puts prostate cancer firmly in Keytruda’s sights Merck puts prostate cancer firmly in Keytruda’s sights

    moving ahead with three pivotal trials of the PD-1 inhibitor alongside AstraZeneca-partnered Lynparza (olaparib), chemotherapy, and anti-hormone drugs. ... The company thinks its phase 3 programme is the largest in the PD-1/PD-L1 category in this tumour

  • BMS isn’t phased by Opdivo’s slowing growth – for now BMS isn’t phased by Opdivo’s slowing growth – for now

    PD-1 inhibitor Opdivo (nivolumab) brought in $1.8bn in the last three months of 2018, a rise of 33% which was well ahead of the level expected by a Reuters ... programme as the PD-1/PD-L1 inhibitor market gets ever more competitive with six drugs now

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Blocking the PD-1/PD-L1 pathway could be an effective immunotherapy approach to improve specific T cell function and lead to a clinical cure,” he suggests. ... also allow it to steal a march on more established PD-1/L1 developers.

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    Along with Zejula, Tesaro also brings with it a pipeline PD-1 inhibitor, TSR-022. ... The company already has Zeluja in combination trials with TSR-022, with all the established PD-1 players also pursuing similar PARP inhibitor combinations.

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Nektar disclosed data from the PIVOT trial of NKTR-214 plus BMS’ PD-1 inhibitor Opdivo (nivolumab) at the ASCO meeting last year, although the two companies were forced to defend ... He also revealed that Nektar has agreed to test NKTR-214 with

More from news
Approximately 21 fully matching, plus 265 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Immuno-oncology: The market opportunity for PD-1/PD-L1s

    Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.

  • How pembrolizumab will change the management of advanced lung cancer

    The Phase III  KEYNOTE-024 trial  assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) ... In light of these findings, it is

  • A stumble, but not a fall – what’s next for Opdivo?

    Until things took a turn for the worse. . Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.

  • ASCO 2015: What you missed in Chicago

    However, the advantage BMS had over Roche and Merck in the programmed cell death pathway space (PD-1/PD-L1) was thrown open over a biomarker debate around activity in ... I think the strength of the Checkmate-057 data[2] will ultimately give Opdivo an

  • Research Partnership

    Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics